Hims & Hers Health, Inc. (HIMS)
| Market Cap | 4.62B -47.9% |
| Revenue (ttm) | 2.87B +29.8% |
| Net Income | -190.84M |
| EPS | -0.83 |
| Shares Out | 234.41M |
| PE Ratio | n/a |
| Forward PE | 23.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,068,634 |
| Open | 19.68 |
| Previous Close | 19.73 |
| Day's Range | 19.18 - 20.16 |
| 52-Week Range | 13.74 - 40.99 |
| Beta | 2.50 |
| Analysts | Hold |
| Price Target | 28.31 (+43.49%) |
| Earnings Date | Nov 9, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter ... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $28.31, which is an increase of 43.49% from the latest price.
News
Hims & Hers Health Faces Legal Woes as Five States Join FTC Lawsuit over Privacy Practices
Hims & Hers Health ($HIMS) is facing legal troubles as five U.S. states joined the Federal Trade Commission (FTC) in a lawsuit alleging that the telehealth platform engaged in deceptive…
Hims & Hers falls -18.6%
Hims & Hers (HIMS) is down -18.6%, or -$4.26 to $18.68.
HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus
Marley Kayden crunches the numbers on Hims & Hers (HIMS) earnings and its worse-than-expected revenue growth. The stock plunged following the opening bell as investors question the telehealth company'...
Hims & Hers (HIMS) Needs Better Profits to Justify Its Price
Hims & Hers ($HIMS) needs better profits to justify its price, in my view. The online healthcare platform grew Q3 revenue 49%, but cash generation weakened. CEO Andrew Dudum said,…
Nvidia, Hims & Hers, JBS, Take-Two, and More Stocks That Explain Today's Market
Hims extends a recent slump after a third-quarter loss, while JBS sinks as Chinese beef import quotas hit the meatpacking business.
Hims & Hers Health Earnings Call Transcript: Q3 2026
Q3 revenue rose 49% YoY, while subscribers dipped QoQ amid deliberate marketing restraint and international brand migrations. Guidance reflects heavy international investment and deferred weight-loss revenue as the platform expands.
Hims & Hers Health Earnings release: Q3 2026
Hims & Hers Health released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Hims & Hers Health Quarterly report: Q3 2026
Hims & Hers Health has published its Q3 2026 quarterly earnings report on November 9, 2026.
Hims & Hers Health Slides: Q3 2026
Hims & Hers Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
Hims & Hers Narrows Sales Outlook
The digital healthcare company narrowed its full-year revenue outlook after third-quarter sales came in lower than expected.
Hims & Hers narrows 2026 revenue forecast as margins contract
Hims & Hers Health cut its full-year core profit forecast on Monday as higher costs tied to branded weight-loss drugs and international expansion pressured margins.
Andrew Huberman built a health empire on independent advice. He told us why he's now joining Hims' board.
Andrew Huberman has built one of the internet's most powerful health audiences by translating science into practical advice on sleep, fitness, hormones, supplements, and longevity. Now, the Stanford n...
Dr. Andrew Huberman Joins Hims & Hers Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading global health and wellness platform, announced the appointment of Andrew Huberman, Ph.D., to the compa...
Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third ...
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (or...
Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits: Grüns®, Medjet®, Tonal™...
What Should Hims & Hers Health, Inc. Investors Know After 14.73% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Hims & Hers Health, Inc. made misleading statements to investors from August 4, 2025 to July 29, 2026; lead plaintiff motions are due November 2, 2026 LOS ANGELES, Oct. 30, 2026 /PRNew...
Kaplan Fox Advises Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm Before the Deadline on November 2, 2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HI...
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Important Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - October 27, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Compa...
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors Who Suffered Losses to Seek a Leadership Role Before November 2, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HI...
Kaplan Fox Announces That Hims & Hers Health, Inc. (HIMS) Investors Have Until November 2, 2026 to Seek Lead Plaintiff Status
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Compa...
Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm About Their Legal Rights Before November 2, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Compa...
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (HIMS) of the Deadline to Seek Lead Plaintiff Status on November 2, 2026
New York, New York--(Newsfile Corp. - October 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Compa...